et al. conducted a study on the impact of Wnt/-catenin signalling on tumor
growth using human tumor xenografts in mice. When treated with OMP-18R5, it
resulted in an inhibition of growth in several human tumors including breast
tumours. Synergy was also observed when OMP-18R5 was combined with several
standard-of-care chemotherapeutic agents – taxol in breast cancer. (Fig 3B) In
tumor recurrence studies, OMP-18R5 treatment together with a high-dose
chemotherapy induced an extended delay in the regrowth of tumors while tumors
treated with control antibody showed rapid regrowth (Fig 3G).